Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protalix BioTherapeutics (PLX) EBIT (2016 - 2025)

Protalix BioTherapeutics has reported EBIT over the past 16 years, most recently at -$336000.0 for Q4 2025.

  • Quarterly results put EBIT at -$336000.0 for Q4 2025, down 108.07% from a year ago — trailing twelve months through Dec 2025 was -$1.2 million (down 235.09% YoY), and the annual figure for FY2025 was -$1.2 million, down 235.09%.
  • EBIT for Q4 2025 was -$336000.0 at Protalix BioTherapeutics, down from $2.1 million in the prior quarter.
  • Over the last five years, EBIT for PLX hit a ceiling of $20.4 million in Q2 2023 and a floor of -$14.3 million in Q4 2023.
  • Median EBIT over the past 5 years was -$2.4 million (2023), compared with a mean of -$1.6 million.
  • Peak annual rise in EBIT hit 469.68% in 2023, while the deepest fall reached 472.18% in 2023.
  • Protalix BioTherapeutics' EBIT stood at -$5.7 million in 2021, then soared by 56.27% to -$2.5 million in 2022, then tumbled by 472.18% to -$14.3 million in 2023, then surged by 129.17% to $4.2 million in 2024, then plummeted by 108.07% to -$336000.0 in 2025.
  • The last three reported values for EBIT were -$336000.0 (Q4 2025), $2.1 million (Q3 2025), and $1.2 million (Q2 2025) per Business Quant data.